The LNP is a complex nanostructured entity that serves to protect the delicate RNA molecule from the harshly degrading nuclease environment in vivo while facilitating intracellular delivery. It comprises several lipid components, including an ionizable lipid that plays a central role in delivery efficacy. Intelligene is diligently refining the formulation of our RNAi drugs to optimize their delivery to target tissues and enhance efficacy.
Exosomes are small (~40-150 nm) extracellular vesicles (EVs) released from all cell types and found in body fluids and cell culture supernatants. They are generated by fusion of a specialized endosome, the multivesicular body (MVB), with the plasma membrane. Exosome has been identified as a perfect therapeutic agent due to their size, ease of crossing cell membranes and ability to communicate in native cellular language.
Our cutting-edge pilot plant in Taipei Bioinnovation Park is focusing on advancing RNA drug development and manufacturing. Our plant specializes in key processes like manufacturing, scaling, and purifying lipid nanoparticles (LNPs) and exosomes (EVs). What's unique is our utilization of exosomes as carriers for RNA drugs, which distinguishes us from conventional methods and holds great promise for new drug development. Our facility complies with rigorous environmental standards for wastewater discharge and is dedicated to sustainable practices.
Engineered exosomes can deliver drugs without eliciting an immune response.
It's highly biocompatible and also biodegradable inside the body,
therefore making it without any potential toxicity issue and become an ideal drug deliver vehicle.
-
Biocompatibility
-
Biodegradability
-
High Penetration
-
Non-immunogenic
